Human Antibodies & Hybridomas

9-11 November 2016, Hilton Hotel, Belfast, Northern Ireland, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 9th November 2016

08.00 Onwards
Arrival & Registration

08.55-09.00
Welcome & Opening Remarks by HAH 2016 Conference Chairman
Mark C. Glassy (Nascent Biologics Inc., San Diego, California, USA)

SESSION 1:
OPENING PLENARY

Moderator: Mark C. Glassy (Nascent Biologics Inc., San Diego, California, USA)

09.00-09.30
Donald Capra Lecture:
‘Human monoclonal antibodies: An ongoing fascinating story’
Professor Michael Steinitz (Hebrew University of Jerusalem, Jerusalem, Israel)

09.30-10.00
‘Applied Healthspan Engineering: A role for antibodies?’
James W. Larrick (Panorama Research Inc., Sunnyvale, California, USA)

10.00-10.30
‘Zmapp and beyond’
Ken Payie (MAPP Biopharmaceuticals Inc., San Diego, California, USA)

10.30-11.00
Coffee Break

SESSION 2:
PLENARY – Technology

Moderator: James W. Larrick (Panorama Research Inc., Sunnyvale, California, USA)

11.00-11.30
‘Converting rabbit hybridoma into recombinant antibodies with effective transient production in an optimized human expression system’
Dr. Tim Welsink (InVivo BioTech Services GmbH, Hennigsdorf bei Berlin, Germany)

11.30-12.00
‘Disease biology driven antibody discovery’
Stephan Fischer (MAB Discovery GmbH, Neuried, Germany)

12.00-12.30
‘CelliGO™ – discovery of therapeutic antibodies for challenging targets using single-B-cell screening by nano-droplet microfluidics’
Adam Woolfe (HiFiBiO BV, Paris, France)

12.30-13.00
‘Integrating Insilico 3-D modelling for the optimization of monoclonal antibodies’
Anthony O’Kane (Fusion Antibodies, Belfast, Northern Ireland, UK)

13.00-14.00
Lunch Break

SESSION 3:
ANTIBODY DRUG CONJUGATES

Moderator: Roger Beerli (NBE-Therapeutics AG, Basel, Switzerland)

14.00-14.25
‘Highly potent, anthracycline-based ADCs generated by enzymatic, site-specific conjugation’
Roger Beerli (NBE-Therapeutics AG, Basel, Switzerland)

14.25-14.50
‘Antibody drug nanoconjugates for the treatment of cancer’
Christopher Scott (Queen’s University of Belfast, Belfast, Northern Ireland, UK)

14.50-15.15
‘Development of the ADC’s for application in gynaecological cancers’
R. Steven Conlan 1, Asa Frostell 2, Tim Fagge 2, Belen Pan Castillo 1, Gareth D. Healey 1, Jetzabel Garcia Parra 1 and Deyarina Gonzalez 1 (1 Swansea University Medical School, Swansea, Wales, UK; 2 GE Healthcare, UK/Sweden)

15.15-15.35
‘De novo antibody generation and selection for development of an ADC’
Jan Schouten (Synthon Biopharmaceuticals BV, Nijmegen, The Netherlands)

15.35-16.00
‘Mirvetuximab soravtansine: Advancing towards phase III’
John Lambert (Immunogen Inc., Waltham, Massachusetts, USA)

16.00-16.15
Tea Break

SESSION 4:
TECHNOLOGY

Moderator: David P. Humphreys (UCB-New Medicines, Slough, Berkshire, UK)

16.15-16.35
‘Next generation VelocImmune® mice’
Lynn Macdonald (Regeneron Pharmaceuticals Inc. Tarrytown, New York, USA)

16.35-16.55
‘Delineation of the epitope: New applications of arrays’
Jaap Willem Back (Pepscan Therapeutics BV, Lelystad, The Netherlands)

16.55-17.15
‘Functional therapeutic antibody hits to challenging targets using the CelliGO™ platform’
Marcel Reichen (HiFiBIO BV, Paris, France)

17.15-17.30
‘Radium-223 in Metastatic Prostate Cancer: The beginning of a new era for targeted radionuclide therapy?’
Joe O’Sullivan (The Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland, UK)

17.30
Bus transport to HAH 2016 Welcome Reception at the Long Gallery in the Parliament Buildings, Stormont Castle

19.30
Bus transport back to Hilton Hotel (arriving 20.00 approx)

 

HAH 2016 Delegates

Login details will be supplied after you have registered for the event.


HAH 2016 Sponsors

  • InCellart
  • Sutro Biopharma
  • Genedata
  • ImmunoGen
  • OMT
  • Kilpatrick Townsend
  • Morphosys
  • MacroGenics
  • Catalent
  • Geneuro
  • Arsanis Biosciences
  • Regeneron
  • Mapp Biopharmaceutical
  • ADC Review
  • hVIVO
  • ModiQuest Research
  • Aldevron
  • HiFiBiO
  • MAB Discovery
  • UCB
  • F-Star
  • Adimab
  • Grifols
  • OncoZine
  • Merck Serono
  • Kadmon
  • Boehringer Ingelheim
  • Polymun Scientific
  • Nascent Biotech
  • Fusion Antibodies

HAH 2016 Downloads

HAH 2016 Leaflet

HAH 2016 Mailing List

Name
E-mail Address
What is 3+2-1?